| Literature DB >> 29419776 |
Ravindra Kolhe1, Ashis K Mondal2, Chetan Pundkar3, Sudharsan Periyasamy-Thandavan4, Bharati Mendhe5, Monte Hunter6, Carlos M Isales7,8, William D Hill9,10, Mark W Hamrick11,12, Sadanand Fulzele13,14.
Abstract
MicroRNAs (miRNAs) are small (18-25 nucleotides), noncoding RNAs that have been identified as potential regulators of bone marrow stromal cell (BMSC) proliferation, differentiation, and musculoskeletal development. Vitamin C is known to play a vital role in such types of biological processes through various different mechanisms by altering mRNA expression. We hypothesized that vitamin C mediates these biological processes partially through miRNA regulation. We performed global miRNA expression analysis on human BMSCs following vitamin C treatment using microarrays containing human precursor and mature miRNA probes. Bioinformatics analyses were performed on differentially expressed miRNAs to identify novel target genes and signaling pathways. Our bioinformatics analysis suggested that the miRNAs may regulate multiple stem cell-specific signaling pathways such as cell adhesion molecules (CAMs), fatty acid biosynthesis and hormone signaling pathways. Furthermore, our analysis predicted novel stem cell proliferation and differentiation gene targets. The findings of the present study demonstrate that vitamin C can have positive effects on BMSCs in part by regulating miRNA expression.Entities:
Keywords: bone marrow stromal cells; miRNA; vitamin C
Mesh:
Substances:
Year: 2018 PMID: 29419776 PMCID: PMC5852762 DOI: 10.3390/nu10020186
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1(a) Human bone marrow stromal cells (BMSCs) cultured in osteogenic medium and stained for mineralized nodules using an Alizarin red S assay; (b) Quantitative analysis of the extent of mineralization in the Alizarin red S assay using elution of dye by 10% (wt./vol.) cetylpyridinium chloride (means ± SD, n = 4) (c) Real time PCR analysis of steady-state levels of mRNA for adipogenic genes PPAR-g and adipsin. Data for each sample were normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. Data (means ± SD, n = 4) are represented as the fold change in expression compared to the control. * p = 0.04, ** p = 0.01.
Figure 2Vitamin C regulates musculoskeletal genes in hBMSCs. Real-time PCR showing dose dependent change in gene expression in hBMSCS after vitamin C treatment (a) Collagen II; (b) BMP-2; (c) BMP-7; (d) RUNX2 and (e) OSX (Osterix). Data (n = 4) are represented as the fold change in expression compared with control (* p = 0.04, # p = 0.001); (f) Intracellular concentration of vitamin C in hBMSCs. hBMSCs cells were treated with 100 μM vitamin C and intracellular accumulation of vitamin C was measured in the control and vitamin C treated cells after 6hrs (n = 6, # p = 0.001).
Selected miRNAs differentially regulated in presence of vitamin C in human bone marrow stromal cells.
| MicroRNA ID/Probeset ID | Fold-Change | |
|---|---|---|
| hsa-miR-3651_st | −3.76469 | 0.000718 |
| hsa-miR-4485_st | −3.70276 | 0.002619 |
| hsa-miR-1275_st | −3.00098 | 0.022393 |
| hsa-miR-4708-5p_st | −2.94613 | 0.002456 |
| hsa-miR-3197_st | −2.86102 | 0.048879 |
| hsa-miR-720_st | −2.81658 | 0.019125 |
| hsa-miR-210_st | −2.75739 | 0.001763 |
| hsa-miR-29b-1-star_st | −2.71192 | 0.032586 |
| hsa-miR-4284_st | −2.49253 | 0.003259 |
| hsa-miR-4479_st | −2.39325 | 0.026759 |
| hsa-miR-3175_st | −2.37271 | 0.013122 |
| hsa-miR-4730_st | −2.36644 | 0.009171 |
| hsa-miR-23a-star_st | −2.26148 | 0.001843 |
| hsa-miR-4321_st | −2.25569 | 0.024075 |
| hp_hsa-mir-3676_st | −2.13436 | 0.008900 |
| hsa-miR-4787-3p_st | −2.05594 | 0.003156 |
| hsa-miR-574-5p_st | −2.02613 | 0.019283 |
| hsa-miR-4492_st | −1.99221 | 0.011873 |
| hsa-miR-345_st | −1.96585 | 0.019316 |
| hsa-miR-1270_st | −1.90283 | 0.047187 |
| hsa-miR-4697-5p_st | −1.83134 | 0.039445 |
| hsa-miR-4433_st | −1.80613 | 0.005357 |
| hp_hsa-mir-4477a_st | 1.83543 | 0.0351021 |
| hp_hsa-mir-548ag-2_st | 1.83747 | 0.0217069 |
| hsa-miR-4727-3p_st | 1.86033 | 0.0446828 |
| hsa-miR-335_st | 1.86288 | 0.0415722 |
| hsa-miR-202_st | 1.87834 | 0.00218913 |
| hsa-miR-4436a_st | 1.96484 | 0.00880198 |
| hp_hsa-mir-532_st | 1.98369 | 0.035662 |
| hsa-miR-3942-5p_st | 1.98754 | 0.002823 |
| hsa-miR-3163_st | 2.0011 | 0.019565 |
| hp_hsa-mir-548f-1_st | 2.01894 | 0.026558 |
| hsa-miR-92a-2-star_st | 2.02393 | 0.003107 |
| hsa-miR-548a-3p_st | 2.02776 | 0.003973 |
| hsa-miR-3121-3p_st | 2.03509 | 0.007681 |
| hsa-miR-3201_st | 2.07949 | 0.006952 |
| hsa-miR-4657_st | 2.07988 | 0.027179 |
| hsa-miR-4704-5p_st | 2.10426 | 0.002415 |
| hsa-miR-1825_st | 2.1387 | 0.028925 |
| hsa-miR-550a-star_st | 2.16711 | 0.017221 |
| hsa-miR-1323_st | 2.21591 | 0.006721 |
| hsa-miR-3927_st | 2.23141 | 0.002801 |
| hsa-miR-509-3-5p_st | 2.2723 | 0.003025 |
| hsa-miR-4423-3p_st | 2.27939 | 0.030500 |
| hsa-miR-890_st | 2.34751 | 0.035107 |
| hsa-miR-4773_st | 2.41459 | 0.002370 |
| hsa-miR-371b-5p_st | 2.42868 | 0.038520 |
| hsa-miR-3128_st | 2.49419 | 0.014536 |
| hsa-miR-1272_st | 2.59151 | 0.033417 |
| hsa-miR-4659a-3p_st | 2.60253 | 0.005995 |
| hsa-miR-377_st | 2.64791 | 0.003494 |
| hsa-miR-550b_st | 2.68252 | 0.013600 |
| hsa-miR-20b-star_st | 2.76807 | 0.004101 |
| hsa-miR-3152-3p_st | 3.2214 | 0.002098 |
| hsa-miR-1208_st | 5.02485 | 0.010838 |
| hsa-miR-4529-3p_st | 12.0104 | 0.009329 |
Figure 3Differential miRNA expression in human bone marrow stromal cells after vitamin C treatment (n = 4 each group). (a) The heat-map showing the differential expression pattern of miRNAs compared to control group; (b) Principle component analysis (PCA) mapping of vitamin C treatment and control samples. Control group (indicated by red color) was clustered distinctly from vitamin C treated group (indicated by blue color).
Figure 4Validation of miRNA array data on randomly picked miRNAs. Real-time PCR showing change in miRNA expression in vitamin C (100 µM) treated samples compared to control (a) miR-29b; (b) miR-3942; (c) miR-4708; (d) miR-371b and (e) miR-3152 (n = 4–6, * p = 0.05, # p = 0.01).
Selected KEGG biological pathways potentially affected by (a) miRNAs down-regulated; and (b) miRNAs up-regulated in the presence of vitamin C in human bone marrow stromal cells.
| Prion diseases | 4.07 × 10−10 | 7 | 7 |
| Morphine addiction | 4.80 × 10−5 | 32 | 17 |
| Amino sugar and nucleotide sugar metabolism | 0.002142 | 16 | 11 |
| Thyroid hormone signaling pathway | 0.002958 | 37 | 17 |
| Cell adhesion molecules (CAMs) | 0.006179 | 43 | 16 |
| Endocytosis | 0.009192 | 63 | 18 |
| Oxytocin signaling pathway | 0.011941 | 53 | 21 |
| Melanogenesis | 0.013774 | 35 | 17 |
| MAPK signaling pathway | 0.013774 | 77 | 22 |
| GABAergic synapse | 0.02274 | 32 | 18 |
| Vasopressin-regulated water reabsorption | 0.035605 | 16 | 11 |
| Adrenergic signaling in cardiomyocytes | 0.035605 | 48 | 22 |
| Glutamatergic synapse | 0.03746 | 34 | 13 |
| Biosynthesis of unsaturated fatty acids | 0.040121 | 7 | 5 |
| Circadian entrainment | 0.046058 | 37 | 16 |
| Mucin type O-Glycan biosynthesis | 1.69 × 10−11 | 11 | 7 |
| Fatty acid biosynthesis | 1.86 × 10−8 | 1 | 1 |
| Glycosphingolipid biosynthesis-lacto and neolacto series | 6.27 × 10−5 | 9 | 8 |
| Fatty acid metabolism | 0.000184 | 7 | 6 |
| Adherens junction | 0.000623 | 25 | 18 |
| Biotin metabolism | 0.010804 | 1 | 1 |
| Arrhythmogenic right ventricular cardiomyopathy | 0.014001 | 21 | 18 |
| Caffeine metabolism | 0.027365 | 2 | 2 |
| Thyroid hormone signaling pathway | 0.027365 | 32 | 21 |
Selected (firsts 50) gene ontology (GO) biological pathways potentially affected by (a) miRNAs down-regulated; and (b) miRNAs up-regulated in the presence of vitamin C in human bone marrow stromal cells.
| organelle | 1.15 × 10−87 | 2073 | 24 |
| ion binding | 7.43 × 10−46 | 1270 | 25 |
| cellular nitrogen compound metabolic process | 7.82 × 10−45 | 1006 | 24 |
| biosynthetic process | 1.56 × 10−32 | 856 | 24 |
| small molecule metabolic process | 1.56 × 10−17 | 489 | 24 |
| cellular protein modification process | 3.92 × 10−15 | 475 | 24 |
| neurotrophin TRK receptor signaling pathway | 2.05 × 10−14 | 70 | 18 |
| synaptic transmission | 2.05 × 10−14 | 121 | 21 |
| nucleic acid binding transcription factor activity | 1.32 × 10−13 | 231 | 24 |
| cellular protein metabolic process | 2.55 × 10−11 | 106 | 20 |
| cell-cell signaling | 1.27 × 10−10 | 162 | 24 |
| catabolic process | 1.50 × 10−10 | 390 | 24 |
| cellular component assembly | 2.41 × 10−9 | 272 | 23 |
| molecular_function | 2.43 × 10−9 | 3342 | 25 |
| gene expression | 2.95 × 10−9 | 116 | 22 |
| symbiosis, encompassing mutualism through parasitism | 4.66 × 10−9 | 111 | 21 |
| post-translational protein modification | 4.93 × 10−9 | 46 | 17 |
| cellular_component | 5.00 × 10−9 | 3383 | 25 |
| blood coagulation | 1.28 × 10−8 | 101 | 20 |
| viral process | 2.94 × 10−8 | 97 | 21 |
| protein binding transcription factor activity | 7.72 × 10−8 | 110 | 22 |
| macromolecular complex assembly | 1.45 × 10−7 | 185 | 23 |
| enzyme binding | 1.74 × 10−7 | 261 | 23 |
| Fc-epsilon receptor signaling pathway | 5.08 × 10−7 | 38 | 15 |
| response to stress | 1.46 × 10−6 | 437 | 25 |
| toll-like receptor TLR1:TLR2 signaling pathway | 2.79 × 10−6 | 21 | 10 |
| toll-like receptor TLR6:TLR2 signaling pathway | 2.79 × 10−6 | 21 | 10 |
| toll-like receptor 10 signaling pathway | 3.62 × 10−6 | 20 | 10 |
| membrane organization | 5.32 × 10−6 | 121 | 23 |
| energy reserve metabolic process | 8.12 × 10−6 | 30 | 13 |
| TRIF-dependent toll-like receptor signaling pathway | 1.46 × 10−5 | 21 | 10 |
| protein complex assembly | 1.95 × 10−5 | 158 | 23 |
| MyD88-independent toll-like receptor signaling pathway | 2.89 × 10−5 | 22 | 11 |
| protein complex | 3.71 × 10−5 | 708 | 24 |
| toll-like receptor 5 signaling pathway | 3.75 × 10−5 | 20 | 10 |
| toll-like receptor 9 signaling pathway | 4.84 × 10−5 | 21 | 10 |
| Golgi lumen | 5.79 × 10−5 | 26 | 11 |
| O-glycan processing | 7.15 × 10−5 | 18 | 12 |
| immune system process | 0.000127 | 309 | 25 |
| mitotic cell cycle | 0.00013 | 74 | 19 |
| cytoskeletal protein binding | 0.000137 | 155 | 22 |
| generation of precursor metabolites and energy | 0.000171 | 74 | 18 |
| regulation of rhodopsin mediated signaling pathway | 0.000201 | 12 | 10 |
| toll-like receptor 4 signaling pathway | 0.000201 | 26 | 11 |
| inositol phosphate metabolic process | 0.000219 | 17 | 9 |
| nucleobase-containing compound catabolic process | 0.000385 | 168 | 24 |
| toll-like receptor 2 signaling pathway | 0.000449 | 21 | 10 |
| platelet degranulation | 0.000563 | 20 | 15 |
| glycosaminoglycan metabolic process | 0.000573 | 26 | 13 |
| platelet activation | 0.000643 | 44 | 18 |
| organelle | 1.67 × 10−95 | 2091 | 47 |
| ion binding | 3.27 × 10−55 | 1303 | 47 |
| cellular nitrogen compound metabolic process | 7.65 × 10−47 | 1010 | 46 |
| biosynthetic process | 1.19 × 10−35 | 866 | 46 |
| gene expression | 7.04 × 10−23 | 151 | 38 |
| cellular protein modification process | 1.18 × 10−22 | 507 | 46 |
| small molecule metabolic process | 7.20 × 10−18 | 488 | 45 |
| nucleic acid binding transcription factor activity | 1.08 × 10−12 | 227 | 43 |
| molecular_function | 2.35 × 10−11 | 3343 | 48 |
| cellular_component | 8.85 × 10−10 | 3375 | 48 |
| cellular protein metabolic process | 1.27 × 10−9 | 101 | 35 |
| enzyme binding | 1.33 × 10−9 | 272 | 43 |
| protein binding transcription factor activity | 5.19 × 10−9 | 114 | 37 |
| cellular component assembly | 9.08 × 10−9 | 268 | 42 |
| viral process | 1.39 × 10−8 | 98 | 31 |
| blood coagulation | 2.54 × 10−8 | 100 | 35 |
| symbiosis, encompassing mutualism through parasitism | 6.42 × 10−8 | 107 | 32 |
| neurotrophin TRK receptor signaling pathway | 9.66 × 10−8 | 56 | 28 |
| catabolic process | 9.95 × 10−8 | 371 | 44 |
| cell death | 3.44 × 10−7 | 195 | 40 |
| protein complex | 5.91 × 10−7 | 724 | 46 |
| enzyme regulator activity | 7.70 × 10−7 | 179 | 36 |
| platelet activation | 9.11 × 10−7 | 52 | 25 |
| membrane organization | 2.77 × 10−6 | 122 | 36 |
| post-translational protein modification | 3.62 × 10−6 | 40 | 23 |
| Fc-gamma receptor signaling pathway involved in phagocytosis | 4.22 × 10−6 | 22 | 13 |
| cytoskeletal protein binding | 1.60 × 10−5 | 160 | 37 |
| nucleoplasm | 1.79 × 10−5 | 233 | 43 |
| cytosol | 2.00 × 10−5 | 523 | 43 |
| cell junction organization | 2.35 × 10−5 | 42 | 24 |
| nucleobase-containing compound catabolic process | 3.39 × 10−5 | 174 | 41 |
| transmembrane transporter activity | 3.63 × 10−5 | 219 | 38 |
| macromolecular complex assembly | 3.63 × 10−5 | 172 | 39 |
| toll-like receptor TLR1:TLR2 signaling pathway | 5.04 × 10−5 | 19 | 15 |
| toll-like receptor TLR6:TLR2 signaling pathway | 5.04 × 10−5 | 19 | 15 |
| TRIF-dependent toll-like receptor signaling pathway | 5.32 × 10−5 | 20 | 16 |
| toll-like receptor 10 signaling pathway | 6.86 × 10−5 | 18 | 15 |
| Fc-epsilon receptor signaling pathway | 8.73 × 10−5 | 33 | 19 |
| cellular component disassembly involved in execution phase of apoptosis | 0.000104 | 15 | 11 |
| vitamin metabolic process | 0.000237 | 21 | 19 |
| MyD88-independent toll-like receptor signaling pathway | 0.000351 | 20 | 16 |
| homeostatic process | 0.000351 | 168 | 41 |
| mitotic cell cycle | 0.000368 | 72 | 34 |
| protein complex assembly | 0.000392 | 150 | 37 |
| water-soluble vitamin metabolic process | 0.000403 | 19 | 17 |
| toll-like receptor 5 signaling pathway | 0.000491 | 18 | 15 |
| energy reserve metabolic process | 0.000538 | 26 | 18 |
| glycerophospholipid biosynthetic process | 0.000692 | 23 | 14 |
| activation of signaling protein activity involved in unfolded protein response | 0.000692 | 18 | 16 |
| transcription initiation from RNA polymerase II promoter | 0.000793 | 52 | 25 |
| toll-like receptor 9 signaling pathway | 0.001896 | 18 | 15 |
Predicated targets of differentially regulated miRNAs of stem cell biology.
| miRNA | No. of Targets | Stem Cell Related Genes | |
|---|---|---|---|
| MiRDB Scan | Target Scan | Common Targets | |
| hsa-miR-3619-5p | 788 | 5948 | PPARGC1B, RUNX3, DLX3, TGFBRAP1, TNFAIP1, TRAF1, TRAF3, TRAF5, TNFAIP8L1, MMP24, SOX8, QSOX2, WNT3 |
| hsa-miR-548a-3p | 947 | 6717 | BMPR2, TGFBR3, TGFBR1, TAB2, TWISTNB, CDC42BPB, IL6R, TRAF6, SMAD4, SMAD1, SMAD5, MMP2, WNT3 |
| hsa-miR-3942-5p | 437 | 3758 | DLX1, BMPR2, BMP2K, TGFB2, IL6R, TNFRSF11A, TRAF3, SMAD1 |
| hsa-miR-4741 | 253 | 4549 | TAB2, SMURF1, SNIP1 |
| hsa-miR-1825 | 253 | 4160 | PPARD, RUNX2, TGFBRAP1, TGFBR1, CD40, SOX6 |
| hsa-miR-1208 | 304 | 4651 | TGFB2, TWISTNB, SMURF1, MMP16, LEPROT |
Figure 5Vitamin C dependent miRNAs mediated signaling in human bone marrow stromal cells. Schematic diagram showing the contribution of key miRNAs in cell proliferation and differentiation of human bone marrow stromal cell.